Marin Biologic Laboratories, Inc.

Comprehensive custom contract research and analytical services provided by MarinBio to support biotechnology and pharmaceutical industries.

Expert services in developing robust cell-based methods for drug discovery, assay development, validation, and optimization.

GMP lot release testing and potency assay development services ensuring the quality, safety, and efficacy of biopharmaceuticals before clinical use or market release.

Comprehensive suite of cell-based, molecular biology, and immunoassay services for antiviral drug discovery, pre-clinical studies, and GMP testing.

Comprehensive stability testing services including thermal, accelerated, intermediate, stress, photostability, and freeze-thaw stability testing for drug substances and products using validated potency bioassays.

Custom cell-based potency assay development services utilizing HEK293 cells and transduction methods for AAV vectors.

Lot release and stability testing services using novel transduction enhancement methods and parallel line analysis (4P curve analysis alternatives).

Robust, rapid, and reproducible one-way and two-way mixed lymphocyte reaction (MLR) bioassays used to monitor immune responses, T-cell proliferation, and immunomodulatory activities of test agents or biologic drugs.

Assays measuring T-cell activation, cytotoxicity, proliferation, exhaustion, suppression, and immune checkpoint expression.

Preclinical ADME-Tox testing services including in vitro and cell-based assays for evaluating absorption, distribution, metabolism, excretion, and toxicity of drug candidates.

Assays to measure the binding affinity of the degrader to the target protein and the E3 ligase.

MarinBio provides validated ELISA services for drug release, stability, IND applications, preclinical and clinical pharmacokinetic (PK) studies, and immunogenicity testing.

An assay measuring intracellular ATP as a sign of metabolically active cells to quantitatively measure proliferation of various human and animal cell lines.

Assays providing a comprehensive understanding of the TPD mechanism from initial target engagement to final protein degradation.

Assays to identify and quantify potential off-target effects and assess immunomodulatory effects of degraders.

A method developed to measure factor dependent proliferation and inhibition of slow growing human umbilical vein endothelial cells, including inhibition by an antibody to VEGF.

Manufacture of drug lots for preclinical and clinical trials under current Good Manufacturing Practices (cGMP).

Assays for assessing tumor cell killing, antibody-dependent cellular cytotoxicity (ADCC), and cytokine secretion by NK cells.

Advanced bioanalytical services providing cell-based drug uptake assays including radioactive tracer assays, fluorescent assays, flow cytometry, and ELISA for small molecules, nanoparticles, and nucleic acids.

An assay designed to measure quantitatively the proliferation of various human and animal cell lines by detecting the reductive environment inside healthy cells.

Assays to measure the effectiveness of a degrader molecule in degrading a target protein and determining minimum compound amounts for biological response.

MarinBio’s digital droplet PCR (ddPCR) service leverages droplet-based sample partitioning and endpoint fluorescence analysis to deliver highly accurate and reproducible nucleic acid quantification for gene copy number variation, viral load, vector copy number determination, reference standard characterization, and pharmacokinetic profiling.

Enzyme-linked immunosorbent assay services for bioanalysis and preclinical testing.

Evaluations of inflammasome activation, mixed lymphocyte reactions, and cytokine production in dendritic cells.

High-sensitivity detection and characterization method for bispecific antibodies and nanobodies.

qPCR bioanalytical testing services for gene expression, viral clearance, and biodistribution studies.

MarinBio provides comprehensive PCR, qPCR, and RT-qPCR bioanalytical testing services for gene expression analysis, miRNA profiling, and mutation detection in drug discovery and development.

Pharmacokinetic and toxicological studies in mice using reference standard proteins produced by transfecting HEK293 cells.

Cellular immunoassay and immunogenicity ADA testing services for drug development programs.

Radioimmunoassay (RIA) contract research and bioanalytical services using active licenses for multiple radioisotopes to support drug discovery, characterization, quantitation, and metabolism studies.

Assay that quantifies the phosphorylation status of a protein in cells using phospho-site-specific antibodies via ELISA or AlphaLISA.

ELISA method development for detecting AAV-derived gene therapy target proteins in human serum samples.

Assays analyzing B-cell surface/intracellular marker expression, antibody secretion, proliferation, and activation.

Assays evaluating macrophage cytokine secretion, surface marker expression, phagocytosis, and polarization phenotypes.

Assay using cell-penetrating peptides designed with kinase substrate sequences to measure active kinase phosphorylation.

Assays measuring neutrophil oxidative burst, CD62L shedding, degranulation, and chemotactic ability.

Pharmacokinetic, toxicological, and immunogenicity (ADA) studies conducted in baboons using ELISA and PK analysis methods.